| Ticker | APUS |
| Long Name | Apimeds Pharmaceuticals US Inc |
| Short Name | Apimeds Pharmaceuticals US |
APUS
Business Profile
Health Care
Healthcare
Major Drug Manufacturers
Major Pharmaceuticals
Pharma
Stocks
US
Apimeds Pharmaceuticals US Inc (APUS) Business Profile
Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company that engages in the development of Apitox, an intradermally administered bee venom-based toxin. It primarily focuses on developing innovative therapies for inflammation and pain management in knee osteoarthritis (OA) and, to a lesser extent, multiple sclerosis (MS). The company was founded on May 11, 2020 and is headquartered in Hopewell, NJ. The company trades on AMEX exchange. The company headquarter is located in USA.